Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250003/S008

Embrace(TM) Hydrogel Embolic System

Instylla, Inc. · Decision date Oct 23, 2026

FDA DECISIONP250003/S008

What did the FDA approve?

FDA records P250003/S008 as a supplement to PMA P250003, with the supplement type “Panel Track”. The recorded decision is approval, dated Oct 23, 2026.

FDA approval order statement

This device is indicated for embolization of hypervascular tumors in peripheral arteries = 5mm and peripheral arterial bleeds in vessels = 6mm.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Cardiovascular
Decision date
Oct 23, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P250003/S008
Regulatory pathway
PMA supplement
Product code
QVG
Decision code
APPR
Decision date
Oct 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250003 · Original PMA

    Embrace(TM) Hydrogel Embolic System

  2. P250003/S008 received

    Application receipt date recorded by FDA.

  3. P250003/S009 · Related supplement

    Embrace Hydrogel Embolic System

  4. P250003/S010 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  5. P250003/S011 · Related supplement

    Embrace Hydrogel Embolic System

  6. P250003/S008 · FDA decision

    Panel Track

Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250003

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA approvalAug 5, 2025FDA
Instylla, Inc.PMA supplementSep 3, 2026FDA
Instylla, Inc.PMA supplementOct 21, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Instylla, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records